» Articles » PMID: 35595725

GLI1 Activates Pro-fibrotic Pathways in Myelofibrosis Fibrocytes

Overview
Journal Cell Death Dis
Date 2022 May 20
PMID 35595725
Authors
Affiliations
Soon will be listed here.
Abstract

Bone marrow (BM) fibrosis was thought to be induced exclusively by mesenchymal stromal cells (MSCs). However, we and others found that neoplastic fibrocytes induce BM fibrosis in myelofibrosis (MF). Because glioma-associated oncogene-1 (GLI1), an effector of the Hedgehog pathway, plays a role in the induction of BM fibrosis, we wondered whether GLI1 affects fibrocyte-induced BM fibrosis in MF. Multiplexed fluorescence immunohistochemistry analysis of MF patients' BM detected high levels of GLI1 in MF fibrocytes compared to MSCs or normal fibrocytes. Immunostaining, RNA in situ hybridization, gene expression analysis, and western immunoblotting detected high levels of GLI1 and GLI1-induced matrix metalloproteases (MMP) 2 and 9 in MF patients BM-derived cultured fibrocytes. Similarly, MF patients' BM-derived GLI1 fibrocytes were found in BMs and spleens of MF xenograft mice. GLI1 silencing reduced the levels of MMP2/9, phosphorylated SMAD2/3, and procollagen-I, and knockdown or inhibition of GLI1 decreased fibrocyte formation and induced apoptosis of both fibrocytes and fibrocyte progenitors. Because Janus kinase (JAK)2-induced STAT3 is constitutively activated in MF and because STAT3 induces GLI1 expression, we sought to determine whether STAT3 activates GLI1 in MF fibrocytes. Imaging analysis detected phosphotyrosine STAT3 in MF patients' BM fibrocytes, and transfection of fibrocytes with STAT3-siRNA or treatment with a JAK1/2 inhibitor ruxolitinib reduced GLI1 and MMP2/9 levels. Chromatin immunoprecipitation and a luciferase assay revealed that STAT3 induced the expression of the GLI1 gene in both MF BM fibrocytes and fibrocyte progenitors. Together, our data suggest that STAT3-activated GLI1 contributes to the induction of BM fibrosis in MF.

Citing Articles

Hedgehog Signaling Pathway in Fibrosis and Targeted Therapies.

Hu Y, Peng L, Zhuo X, Yang C, Zhang Y Biomolecules. 2025; 14(12.

PMID: 39766192 PMC: 11727624. DOI: 10.3390/biom14121485.


Imperatorin Suppresses Aberrant Hedgehog Pathway and Overcomes Smoothened Antagonist Resistance via STAT3 Inhibition.

Wang J, Cheng H, Zhao X, Zhang X, Ding X, Huang T Drug Des Devel Ther. 2024; 18:5307-5322.

PMID: 39588392 PMC: 11586484. DOI: 10.2147/DDDT.S482894.


Positive GLI1/INHBA feedback loop drives tumor progression in gastric cancer.

Sun J, Zhu W, Luan M, Xing Y, Feng Z, Zhu J Cancer Sci. 2024; 115(7):2301-2317.

PMID: 38676428 PMC: 11247559. DOI: 10.1111/cas.16193.


Exploring the molecular mechanisms between lymphoma and myelofibrosis.

Wang J, Li Y Am J Transl Res. 2024; 16(3):730-737.

PMID: 38586105 PMC: 10994807. DOI: 10.62347/NWJO7078.


Cell type-specific transforming growth factor-β (TGF-β) signaling in the regulation of salivary gland fibrosis and regeneration.

Munoz Forti K, Weisman G, Jasmer K J Oral Biol Craniofac Res. 2024; 14(3):257-272.

PMID: 38559587 PMC: 10979288. DOI: 10.1016/j.jobcr.2024.03.005.


References
1.
Tefferi A . Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005; 23(33):8520-30. DOI: 10.1200/JCO.2004.00.9316. View

2.
Ruiz i Altaba A, Sanchez P, Dahmane N . Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer. 2002; 2(5):361-72. DOI: 10.1038/nrc796. View

3.
Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos C, Newberry K, Prijic S . Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016; 213(9):1723-40. PMC: 4995084. DOI: 10.1084/jem.20160283. View

4.
de la Guardia R, Correa J, Lopez-Millan B, Juan M, Bueno C, Cervantes F . Detection of inflammatory monocytes but not mesenchymal stem/stromal cells in peripheral blood of patients with myelofibrosis. Br J Haematol. 2017; 181(1):133-137. DOI: 10.1111/bjh.14507. View

5.
Furtek S, Backos D, Matheson C, Reigan P . Strategies and Approaches of Targeting STAT3 for Cancer Treatment. ACS Chem Biol. 2016; 11(2):308-18. DOI: 10.1021/acschembio.5b00945. View